每经AI快讯，1月20日，朗姿股份(002612.SZ)公告称，朗姿股份发布2025年度业绩预告，预计归属于上 市公司股东的净利润为9.00亿元~10.50亿元，比上年同期增长245.25%~302.80%。报告期内，公司处置 若羽臣部分股票并将剩余股权转为交易性金融资产，确认投资收益及公允价值变动损益，导致净利润大 幅上升。 ...

作为医美行业的领军企业，爱美客通过一系列创新实践，既实现了自身的高质量发展，更引领了行业的 转型方向。未来，随着国际化布局的深化与新技术、新产品的持续落地，公司将继续以创新为核心驱动 力，持续辐射产业生态，为健康中国建设与全球医美行业的进步贡献更多力量。 以上实践取得了技术、行业与社会多方面的成果。公司核心产品市场占有率稳居前列，"濡白天使"作为 国家重点研发计划成果，累计产值已突破30亿元；2024年10月，医用含聚乙烯醇凝胶微球的交联透明质 酸钠凝胶（商品名：嗗科拉）获批，进一步丰富了高端产品线。产学研协同显著提升了公司竞争力与行 业整体水平。同时，公司于2025年获中国整形美容协会授予"2025中国医疗美容行业领袖企业奖"，体现 了对其行业引领地位与创新实力的肯定。在近3000亿元规模的中国医美市场中，爱美客带动行业从价格 竞争转向价值竞争，促进了规范化与高质量发展。在社会价值上，公司积极履行责任，2024年捐赠500 万元发起"幸福明天·新美妈妈"公益项目；2025年捐赠100万元驰援香港大埔火灾受灾同胞，践行"科技 向善"，让创新成果惠及民生。 爱美客（300896）是国内最早聚焦生物医用软组织修复 ...

Group 1 - The core viewpoint of the article highlights that Han Commercial Group has experienced a consecutive two-day trading limit increase, indicating strong market interest and performance [1] - The stock reached a trading limit at 9:59 AM with a transaction volume of 416 million yuan and a turnover rate of 12.75% [1] - Recent favorable policies related to the infant and child sector have contributed to the market's attention on Han Commercial Group, which is expanding into the assisted reproductive field and holds licenses for reproductive hospitals and stem cell research [1] Group 2 - The company has made breakthroughs in medical aesthetic materials, aligning its business with the growing market interest in healthcare consumption [1] - The convergence of multiple concepts within the company's operations has sparked increased market focus and investor interest [1]

顶端新闻·河南商报评论员 张丽 医美行业的税收规则，迎来了重要调整。2026年1月1日起，《中华人民共和国增值税法》及其实施条例 正式施行，明确营利性美容医疗机构提供的医疗美容服务，需依法缴纳增值税。 这次调整是回归税收公平的重要举措，意在进一步规范医美行业的税收秩序，核心是推动医美行业实现 公平竞争与规范发展。 过去，因税收优惠政策未明确排除营利性美容医疗机构，这类机构实际上一直享受着免税优惠。对医疗 机构免税的初衷，本是保障公众基本医疗需求，带有公益性，只不过营利性美容医疗机构借用政策搭了 个便车。 此次新规明确要求，营利性美容医疗机构不再享受免税政策，厘清了过去的"模糊地带"，既是税收制度 本义的回归，也让行业税收征管更加公平。 政策调整，将加速行业洗牌，推动市场向合规化方向发展。新政落地后，医美行业成本结构将更加透 明，以往部分机构靠虚列成本来掩盖利润等操作可能行不通了。若机构不规范成本核算，将面临税负成 本增加与罚款风险。 顶端新闻·河南商报评论员认为，随着综合税负成本上升，净利润偏低的中小机构或因承受不住资金压 力退出市场。但从长远看，依法纳税、技术领先、服务优质的合规机构，将在公平的税收环境中， ...

Core Viewpoint - The rapid development of the medical beauty industry is accompanied by various malpractices, including false advertising, low-price traps, and illegal medical practices, prompting consumer protection agencies to issue warnings and guidelines for consumers [1][2]. Group 1: Industry Challenges - The medical beauty industry is experiencing a surge due to the "beauty economy," but it is also plagued by issues such as false advertising and low-price traps [1]. - Common tactics include exaggerated claims about doctor qualifications, fabricated celebrity endorsements, and misleading product effectiveness [1]. - Low-price promotions, such as "199 yuan water light needle" and "299 yuan double eyelid surgery," often lead to consumers facing significantly higher costs upon arrival at the clinic [1]. - Some institutions collaborate with financial platforms to offer "medical beauty loans" that appear attractive but hide high-interest rates and fees, leading to financial burdens for consumers [1]. Group 2: Consumer Protection Guidelines - The Xiamen Consumer Protection Committee has proposed five guidelines to help consumers avoid pitfalls in the medical beauty sector [3]. - Verify the qualifications of the medical institution, ensuring they possess the necessary licenses and that the performing physician is registered [3]. - Confirm the compliance of products used in procedures, checking for proper registration and labeling [3]. - Avoid impulsive purchases driven by marketing tactics, and make informed decisions based on personal needs and health [3]. - Sign formal contracts that clearly outline project details, costs, and guarantees, and retain all communication records [3]. - Steer clear of illegal medical beauty services, such as home visits or unlicensed private studios, which pose significant risks [3]. Group 3: Post-Procedure Actions - In cases of unsatisfactory results or physical harm post-procedure, consumers should retain evidence such as medical records and payment receipts [4]. - Initial communication with the medical beauty institution should focus on seeking repairs, refunds, or compensation, with all interactions documented [4]. - If negotiations fail, consumers can file complaints with relevant administrative departments or seek mediation through medical dispute committees [4].

Group 1 - The company held its 37th meeting of the fifth board of directors on January 16, 2026, to discuss and approve a proposal regarding joint investment with related parties [2][4] - The proposal aims to accelerate the national layout strategy of the company's medical beauty business and establish a long-term incentive and restraint mechanism for key employees [3][8] - The company has been utilizing employee stock ownership platforms to jointly invest in new medical beauty institutions since July 2017, with the full subsidiary, Langzi Medical Management Group Co., Ltd., acting as the general partner [3][8] Group 2 - The board approved the proposal with a unanimous vote, with one related director abstaining from the vote [4][9] - The independent directors held a special meeting and agreed that the pricing and terms of the related transactions are fair and do not harm the interests of the company or its minority shareholders [29][30] - The expected investment amounts for key personnel involved in the employee stock ownership platforms were detailed, with specific figures provided for each individual [10][12][14][15]

证券日报网讯 1月19日，爱美客在互动平台回答投资者提问时表示，截至目前公司已形成了基于透明质 酸钠的系列皮肤填充剂、基于聚乳酸的皮肤填充剂、基于聚对二氧环己酮面部埋植线，以及基于神经除 皱肉毒毒素生物制剂的丰富的产品线。公司凭借全方位且具有差异化的产品矩阵来满足用户多元化的需 求。 （文章来源：证券日报） ...

证券日报网讯 1月19日，爱美客在互动平台回答投资者提问时表示，关于公司经营业绩情况，请关注公 司后续披露的定期报告。 （文章来源：证券日报） ...

Core Viewpoint - *ST Jinbi (sz002762) experienced a limit-up on January 19, 2026, reaching a price of 7.29 yuan, with a 4.9% increase, and a total market capitalization of 2.577 billion yuan, driven by governance structure optimization, improved institutional systems, and stable fund management [1] Group 1: Governance and Institutional Improvements - The company is undergoing a governance transformation by abolishing the supervisory board and enhancing the functions of the audit committee, aligning with the new Company Law, which is expected to improve decision-making efficiency [1] - The revision of multiple procedural rules for the shareholders' meeting and board of directors aims to standardize the decision-making process for related transactions, which is likely to enhance governance efficiency in the long term [1] Group 2: Financial Management and Investor Confidence - The company has demonstrated stable financial management, with idle funds being invested and returned on schedule, and risk control measures being well-established, which has bolstered investor confidence [1] - Despite current performance issues, the potential for improvement in operational conditions is anticipated as the governance system is refined [1] Group 3: Industry Context and Market Reaction - The mother and baby consumption and medical beauty industries show significant development potential, contributing to the stock's performance [1] - On the day of the limit-up, related stocks in the mother and baby and medical beauty sectors exhibited active performance, indicating a sector-wide response [1] - Although technical analysis data is limited, the inflow of funds appears to be attracted by the company's improvements, leading to the stock's limit-up, reflecting market expectations for future development post-governance transformation [1]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the competitive advantage of Qian Dama through its "community small store + daily clearance mechanism + warehouse and cold chain" model, which enhances supply stability and operational efficiency [3][24][35] - The report emphasizes the importance of emotional consumption themes and identifies high-quality companies in high-growth sectors, recommending specific companies across various segments [6][37] Summary by Sections Industry Overview - The retail and social service indices reported a decline of 1.47% and an increase of 1.53% respectively during the week of January 12-16, 2026 [5][13] - The internet e-commerce sector showed the highest growth, with a year-to-date increase of 11.18% [16][19] Company Highlights - Qian Dama has submitted its IPO application to the Hong Kong Stock Exchange, focusing on fresh food retail in the South China market, with a GMV of 9.8 billion yuan in 2024, significantly outperforming its competitors [24][25] - The company operates 2,983 stores, with 2,898 being franchise stores, contributing over 90% of its revenue [25][31] - The report recommends several companies based on their performance and market positioning, including: - Chaohongji, expected to achieve a net profit of 436-533 million yuan in 2025, driven by brand upgrades and channel expansion [39][43] - Meilitiantian Medical Health, projected to see a revenue increase of 28.2% in FY2025H1 [39] - Zhou Dafu, focusing on product structure optimization and store upgrades [39] Investment Themes - Investment Theme 1: Focus on high-end gold and fashion jewelry brands, recommending Chaohongji and Laopu Gold [6][37] - Investment Theme 2: Emphasize retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Aiyingshi [6][37] - Investment Theme 3: Highlight domestic beauty brands that meet emotional value and safety innovation, recommending Maogeping and Pola [6][37] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending Meilitiantian Medical Health and Aimeike [6][37]